Subjects: Opioid-Related Disorders -- drug therapy - Digital Collections - National Library of Medicine Search Results

1. The integration of harm reduction and healthcare: implications and lessons for healthcare reform

Author(s):: Schafer, Peter, author
Calvo, Michele, author
Publication:: New York, N.Y. : New York Academy of Medicine, June 2015
Subject(s):: Behavioral Medicine -- organization & administration
Community Health Services -- organization & administration
Delivery of Health Care, Integrated -- organization & administration
Harm Reduction
Patient-Centered Care
Primary Health Care -- organization & administration
Analgesics, Opioid -- poisoning
Drug Overdose -- drug therapy
Health Care Reform
Health Policy
Health Services Accessibility
Health Services Needs and Demand
Interprofessional Relations
Medically Underserved Area
Naloxone -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opioid-Related Disorders -- drug therapy
Organizational Case Studies
Patient Acceptance of Health Care
Poverty Areas
Professional Practice Location
Quality of Health Care
Social Determinants of Health
Substance Abuse, Intravenous
Substance-Related Disorders -- therapy
Syringes
Humans
New York
United States

2. The role of community health centers in addressing the opioid epidemic

Author(s):: Zur, Julia, author
Tolbert, Jennifer, author
Sharac, Jessica, author
Markus, Anne, author
Publication:: San Francisco, CA : Henry J. Kaiser Family Foundation, July 2018
Subject(s):: Community Health Centers -- statistics & numerical data
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Drug Overdose -- epidemiology
Inservice Training
Medicaid
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment
Practice Patterns, Physicians'
Prescription Drug Misuse -- statistics & numerical data
State Government
Humans
United States

3. Expanding access to naloxone: a review of distribution strategies

Author(s):: Weiner, Janet, author
Murphy, Sean , author
Behrends, Czarina, author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2019
Subject(s):: Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Services Accessibility
Naloxone -- supply & distribution
Naloxone -- therapeutic use
Opioid-Related Disorders -- drug therapy
Community Health Services
Emergency Responders
Nonprescription Drugs
Opioid-Related Disorders -- epidemiology
Pharmacies
Humans
United States

4. The opium and whisky habits, and their cure

Author(s):: Woolley, B. M. (Basil M.), 1834- author
Publication:: Atlanta, Ga. : Constitution Job Office, [1889?]
Subject(s):: Opioid-Related Disorders -- drug therapy
Alcohol-Related Disorders -- drug therapy
Nostrums

5. The opium habit: its successful treatment by the Avena sativa : a paper read before the New York State Medical Society, February 9th, 1882, with additions, giving a fuller description of its therapeutic action in different diseases, etc

Author(s):: Sell, E. H. M. (Edward Herman Miller), 1832-1920, author
Publication:: Jersey City : The Evening journal print, 1883
Subject(s):: Opioid-Related Disorders -- drug therapy
Phytotherapy
Avena

6. Substance use disorder in America: research to practice, and back again addressing the gaps in evidence-based policy and practice

Author(s):: Miclette, Matthew, author
Cuan, Isabella, author
Meisel, Zachary F., author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, August 2017
Subject(s):: Evidence-Based Medicine
Health Policy
Opioid-Related Disorders -- epidemiology
Opioid-Related Disorders -- therapy
Substance-Related Disorders -- epidemiology
Substance-Related Disorders -- therapy
Buprenorphine -- therapeutic use
Continuity of Patient Care
Health Services Accessibility
Inappropriate Prescribing
Insurance, Health, Reimbursement
Medicaid
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opioid-Related Disorders -- drug therapy
Pain management
Patient Participation
Policy Making
Research
Humans
United States

7. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options

Publication:: [Boston, MA] : Institute for Clinical and Economic Review, July 2014
Subject(s):: Analgesics, Opioid -- therapeutic use
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Delivery of Health Care
Health Policy
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment -- economics
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- rehabilitation
Analgesics, Opioid -- administration & dosage
Analgesics, Opioid -- adverse effects
Budgets
Cohort Studies
Cost-Benefit Analysis
Counseling
Criminal Law
Drug Combinations
Drug Costs
Health Services Accessibility
Insurance Coverage
Medicaid
Medicare
Patient Care Team
Patient-Centered Care
Practice Guidelines as Topic
Treatment Outcome
Humans
New England
United States

8. Show me the money: economic evaluations of opioid use disorder interventions

Author(s):: Murphy, Sean M., author
Polsky, Daniel, author
Meisel, Zachary, author
Mitchell, Julia, author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016
Subject(s):: Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Buprenorphine -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Reward
Humans
United States

9. Primary care: on the front lines of the opioid epidemic

Author(s):: Bachhuber, Marcus A., author
Weiner, Janet, author
Mitchell, Julia, author
Samet, Jeffrey, author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, August 2016
Subject(s):: Opioid-Related Disorders -- diagnosis
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- epidemiology
Primary Health Care
Analgesics, Opioid -- therapeutic use
Buprenorphine -- therapeutic use
Chronic Disease
Comorbidity
Continuity of Patient Care
Delivery of Health Care, Integrated
HIV Infections -- prevention & control
HIV Infections -- transmission
Naloxone -- therapeutic use
Needle-Exchange Programs
Patient Care Management
Patient Care Team
Physician's Role
Prescription Drug Misuse
Humans
United States

10. The opium habit and its cure, and what others say of his cures

Author(s):: Woolley, B. M. (Basil M.), 1834-
Publication:: [Atlanta?] : Atlanta Constitution Print., [1879?]
Subject(s):: Opioid-Related Disorders -- drug therapy
Nostrums

11. MAT in community health centers

Author(s):: Newman, Sandra, author
Fisher, Tammy, author
Publication:: [Oakland, Calif.] : California Health Care Foundation, January 2019
Subject(s):: Community Health Centers -- economics
Insurance, Health, Reimbursement
Opiate Substitution Treatment -- economics
Opioid-Related Disorders -- drug therapy
Reimbursement Mechanisms
Buprenorphine -- economics
Buprenorphine -- therapeutic use
Financing, Government
Medication Therapy Management
Primary Health Care -- economics
Value-Based Purchasing
Humans
California
United States

12. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):: Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

13. Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate

Publication:: Washington, DC : United States Government Accountability Office, October 2017
Subject(s):: Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Outcome Assessment (Health Care)
Community-Institutional Relations
Buprenorphine -- therapeutic use
Inservice Training
Insurance Coverage
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Prescription Drug Diversion -- prevention & control
Humans
United States
United States. Department of Health and Human Services.

14. Why health plans should go to the "MAT" in the fight against opioid addiction

Author(s):: Elitzer, Julia, author
Tatar, Margaret, author
Publication:: [Oakland, Calif.] : California Health Care Foundation, September 2017
Subject(s):: Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Cost Savings
Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Care Costs
Health Services Accessibility
Healthcare Disparities
Inappropriate Prescribing -- prevention & control
Insurance Coverage -- legislation & jurisprudence
Managed Care Programs
Medicaid
Mental Health Services -- legislation & jurisprudence
Methadone -- therapeutic use
Naloxone
Naltrexone -- therapeutic use
Neonatal Abstinence Syndrome -- drug therapy
Opioid-Related Disorders -- epidemiology
Patient Care Management
Prescription Drug Diversion
State Government
Humans
California
United States

15. Overcoming data-sharing challenges in the opioid epidemic: integrating substance use disorder treatment in primary care

Publication:: [Oakland, Calif.] : California Health Care Foundation, July 2018
Subject(s):: Confidentiality
Opioid-Related Disorders -- therapy
Primary Health Care
Electronic Health Records -- legislation & jurisprudence
Informed Consent -- legislation & jurisprudence
Information Dissemination -- legislation & jurisprudence
Opioid-Related Disorders -- drug therapy
State Government
Humans
California
Connecticut
Oregon
United States
United States.

16. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 2, 2022
Subject(s):: Buprenorphine -- therapeutic use
Drug Prescriptions -- statistics & numerical data
Drug Utilization -- statistics & numerical data
Drug Utilization -- trends
Opioid-Related Disorders -- drug therapy
Practice Guidelines as Topic
Scope of Practice
United States
United States. Department of Health and Human Services.

17. Medical profession endorse Manine in the treatment of morphinism or the drug "habit" disease

Publication:: St. Louis, Mo. : The Manine Medicine Company, [1913?]
Subject(s):: Opioid-Related Disorders -- drug therapy
Nonprescription Drugs

18. Dear Doctor, I wish to call your attention to our remedy, Manine, for the treatment and cure of that diseased condition of the nervous system caused by the use of morphine, laudanum, heroin or opium in any of its forms

Author(s):: Manine Medicine Company, author.
Publication:: St. Louis, Missouri : Manine Medicine Company, [1913?]
Subject(s):: Opioid-Related Disorders -- drug therapy
Nonprescription Drugs

19. Study finds increased use of medications for OUD among Medicaid enrollees in 11 states

Publication:: Washington, DC : AcademyHealth, July 2021
Subject(s):: Medicaid -- statistics & numerical data
Opiate Substitution Treatment -- statistics & numerical data
Opioid-Related Disorders -- drug therapy
United States

20. Learning from COVID-19: how pandemic-era policies for methadone prescribing could improve opioid treatment

Author(s):: Suen, Leslie W., author
Nguyen, Oanh K., author
Knight, Kelly Ray, 1969- author
Publication:: [Oakland, California] : California Health Care Foundation, April 2022
Subject(s):: COVID-19
Methadone -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Prescriptions
Health Policy
California

21. Opioid use disorder: endpoints for demonstrating effectiveness of drugs for treatment

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, October 2020
Subject(s):: Analgesics, Opioid
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

22. Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees

Publication:: Washington, DC : United States Government Accountability Office, January 2020
Subject(s):: Analgesics, Opioid -- supply & distribution
Analgesics, Opioid -- therapeutic use
Health Services Accessibility
Medicaid -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
Centers for Medicare & Medicaid Services (U.S.)

23. Geographic disparities affect access to buprenorphine services for opioid use disorder

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, January 2020
Subject(s):: Buprenorphine -- supply & distribution
Health Services Accessibility
Medically Underserved Area
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services
United States. Substance Abuse and Mental Health Services Administration

24. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach

Author(s):: Aronowitz, Shoshana V., author
Behrends, Czarina Navos, author
Lowenstein, Margaret, author
Schackman, Bruce, author
Weiner, Janet, author
Publication:: Philadelphia, PA : Leonard Davis Institute of Health Economics, January 2022
Subject(s):: Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Health Services Accessibility
United States

25. Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic

Author(s):: Au-Yeung, Caroline M., author
Blewett, Lynn A., author
Winkelman, Tyler N.A., author
Publication:: New York, NY : Milbank Memorial Fund, October 2021
Subject(s):: Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
COVID-19
Health Policy
Methadone -- therapeutic use
Naltrexone -- therapeutic use
United States

26. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, February 2019
Subject(s):: Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
Buprenorphine -- administration & dosage
Clinical Trials as Topic
Delayed-Action Preparations
Narcotic Antagonists
Opiate Substitution Treatment
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

27. Opioid use decreased in Medicare Part D, while medication-assisted treatment increased

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2019
Subject(s):: Analgesics, Opioid -- therapeutic use
Medicare Part D
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Overdose -- drug therapy
Drug Utilization -- trends
Forecasting
Inappropriate Prescribing
Naloxone -- therapeutic use
State Government
Humans
United States

33. Catalyzing Medicaid policy research with T-MSIS Analytic Files (TAF): learnings from year 1 of the Medicaid Data Learning Network (MDLN)

Author(s):: Gordon, Sarah, (Of Boston University), author
Johnson, Annaliese, author
Kennedy, Susan, (Of AcademyHealth), author
McConnel, John, (Of Oregon Health & Science University), author
Schpero, William, author
Publication:: Washington, DC : AcademyHealth, May 15, 2023
Subject(s):: Datasets as Topic
Health Policy
Health Services Research
Medicaid -- statistics & numerical data
Ethnicity
Fee-for-Service Plans
Health Expenditures
Information Storage and Retrieval
Managed Care Programs
Maternal Health
Opioid-Related Disorders -- drug therapy
Racial Groups
Reproductive Health
Utilization Review
United States

34. The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, May 2023
Subject(s):: Buprenorphine
Buprenorphine, Naloxone Drug Combination
Government Regulation
Medicare Part D
Opioid-Related Disorders -- drug therapy
United States

35. Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2023
Subject(s):: Ethnic and Racial Minorities -- statistics & numerical data
Government Regulation
Health Inequities
Healthcare Disparities
Medicaid
Morphinans -- supply & distribution
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

36. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023
Subject(s):: Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States

37. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2023
Subject(s):: Government Regulation
Medicare
Opiate Overdose -- prevention & control
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

38. The opium habit: its successful treatment by the Avena sativa, a paper read before the New York State Medical Society, February 9, 1882

Author(s):: Sell, E. H. M. (Edward Herman Miller), 1832-1920, author
Publication:: Jersey City : Evening Journal Print, 1882
Subject(s):: Opioid-Related Disorders -- drug therapy
Avena
Plant Extracts -- therapeutic use